Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison

Ähnliche Einträge

• Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
  von: Manish R. Bhise, et al.
  Veröffentlicht: (2025)
• Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
  von: Alpana P. Shukla, et al.
  Veröffentlicht: (2025)
• Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
  von: Theresa Hunter Gibble, et al.
  Veröffentlicht: (2025)
• Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
  von: Domenica M. Rubino, et al.
  Veröffentlicht: (2025)
• Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide
  von: Caroline Swift, et al.
  Veröffentlicht: (2024)